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ABSTRACT
Background: Background/Aims: The increasing use of capsule endoscopy (CE) to examine the gastrointestinal tract highlights the need 
to establish intestinal preparations that ensure optimal visualization while maximizing patient adherence. Thus, we assessed whether 
bowel preparation involving dietary restriction and a booster regimen produces adequate CE visualization in a real-world clinical setting.
Methods: We conducted a randomized, double-blind, prospective study of CE procedures at 2 tertiary-care centers. Patients were allo-
cated to 3 groups: group 1 followed a clear liquid diet and fasting-based bowel preparation for the exploration (n = 55); group 2 followed 
the same procedure as group 1 and then ingested 1 L of a polyethylene glycol (PEG)/ascorbic acid booster solution when the capsule 
reached the small intestine (n = 55); and group 3 followed the same procedure but ingesting only 0.5 L of the booster solution (n = 56). 
The quality of visualization and the average gastric, orocecal and small-bowel transit times were evaluated.
Results: A total of 166 patients participated in the study. Significantly higher quality of visualization (Park score) was obtained in group 
3 (2.28 ± 0.59) than in group 1 (1.84 ± 0.54, P < .001), while there were no significant differences in the average gastric (range: 36.58-
48.32 min, P = .277), orocecal (range: 322.58-289.45 min, P = .072), and small-bowel transit time (range: 280.71-249.95 min, P = .286) 
between the 3 groups.
Conclusions: Following a clear liquid diet and fasting-based bowel preparation for CE exploration, administering a booster solution of 
PEG/ascorbic acid after the capsule had reached the small intestine improves mucosal visualization and cleansing without affecting 
capsule transit times.
Keywords: Capsule endoscopy, PEG/ascorbate booster, mucosa visualization, gastric transit time
INTRODUCTION
Capsule endoscopy (CE) is a procedure that is now often 
used to study conditions affecting the small intestine, 
offering certain benefits over conventional endoscopy 
examination.1 CE still requires cleansing of the diges-
tive tract for optimal visualization, and while active bowel 
preparation for CE may achieve this,2 these regimens are 
often not well tolerated by patients and produce adverse 
events (e.g., dizziness, vomiting, etc.).3 Indeed, such pro-
tocols may ultimately be associated with poor patient 
adherence and even abandonment, potentially provoking 
poorer visualization and failure of the exploration, or non-
attendance. Thus, the optimal patient preparation for CE 
remains unclear, highlighting the need to establish an effi-
cient, standardized, and user-friendly preparative protocol.
There is evidence that bowel preparation with purga-
tive agents prior to CE improves small-bowel mucosal 
visualization when compared to a preparation simply 
involving a clear liquid diet and overnight fasting. These 
improvements are generally achieved without affecting 
the CE completion rate, the capsule’s gastric transit time 
(GTT), or its small-intestine transit time (SITT). A large 
body of evidence supports the use of polyethylene glycol 
(PEG) 4-8 and, in particular, the combined use of PEG with 
other agents such as simethicone or ascorbic acid.1,9-14  
Of these, there is evidence that combining PEG with 
ascorbic acid is better tolerated by patients, producing 
fewer adverse events and hence, better patient adher-
ence.11 However, to date, no large, multicenter, random-
ized-controlled trials have been carried out to validate the 
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use of these protocols or evaluate the ideal dose/volume 
of PEG or the most appropriate timing of bowel prepara-
tion before CE. Indeed, not all studies found benefits when 
using such active bowel preparations in terms of visual-
ization quality and diagnostic performance.15-18 Hence, 
more efforts are clearly necessary to establish a standard 
preparative protocol for CE.
Significantly, in many studies, patients are also required 
to ingest a booster during the exploration in order to 
propel the capsule through the small-bowel to reach 
the colon, and to ensure its rapid recovery. As such, we 
speculated that the use of a PEG booster after capsule 
ingestion, in conjunction with a clear liquid diet prepara-
tion the day prior to the procedure and a 10 h overnight 
fast, may be sufficient to produce optimal CE visibility 
of the small-bowel mucosa. Should this be the case, it 
might provide an alternative to the pre-ingestion PEG 
cleansing protocol, combining the comfort of a less 
stringent preparation with the visual quality of the latter. 
Accordingly, the main aim of this study was to evaluate 
the quality of mucosal visualization and cleansing when a 
booster solution of PEG plus ascorbic acid was adminis-
tered after ingestion of the capsule, and following a clear 
liquid diet and overnight fasting bowel preparation for CE 
the day prior to the examination, in a real-world clinical 
setting.
MATERIALS AND METHODS
Patients and Study Design
This is a randomized, double-blind, prospective study on 
patients aged between 16 and 92 with various clinical indi-
cations that required CE. The patients who participated in 
this study were recruited between January 2017 and April 
2018. All patients on whom videocapsule endoscopy was 
carried out at the Manoph and iCUF tertiary-care centers 
(2 affiliated healthcare centers) provided their informed 
consent were initially included in the study. Each of the 
patients was randomly assigned to one of 3 groups by 
MMS through a double-bind randomization prior to the 
examination. The clinician performing the intervention 
remained blind to this assignation and was responsible 
for the capsule’s real-time visualization throughout the 
intervention and for establishing the time at which the 
booster solution was administered. The patients in group 
1 followed a commonly used bowel preparation prior to 
the exploration (n = 55), which involved 3 days without 
iron supplement intake and with light meals, adhering to a 
clear liquid diet from the afternoon of the day prior to the 
examination, and fasting for 10 h before the procedure 
was performed. The patients in group 2 followed the 
same bowel preparation prior to the examination as that 
followed by patients in group 1, but they also ingested 
a 1 L booster solution of PEG/ascorbic acid (prepared in 
water: Moviprep®: Supplementary File) when the capsule 
had reached the small intestine, as verified through real-
time visualization by the clinician performing the inter-
vention (n = 55). Finally, the patients in group 3 followed 
the same procedure as those in group 2, except they 
ingested a smaller volume of the booster solution, 0.5 L 
(n = 56). Patients who did not comply with the prescribed 
preparation or on whom a different capsule model from 
those established were used were excluded from the 
study.
All the patients recruited to this study provided their 
informed consent (or that of their legal guardians) prior 
to participating in this study, which was carried out in 
accordance with the guidelines laid down in the Helsinki 
declaration and with the approval of the 2 hospital’s local 
ethical committee.
Procedures and Study Design
CE examinations were carried out either using the 
PillCam(r) SB3 capsule endoscopy system (Given Imaging, 
Yokneam, Israel) or the MiroCam® Capsule endoscopy 
system (Intromedic, Seoul, Korea).
In the absence of a more universally accepted standard, 
small-intestine cleanliness/quality of visualization was 
assessed blindly, in accordance with a scale devised pre-
viously.19 In this scale, referred to as the Park score, the 
cleansing score is considered on a scale of 0 to 3, where 
3 is better, and 0 is worse. To obtain this score, representa-
tive images from the small-bowel were selected in series 
at 5 min intervals, and the 2 parameters were evaluated in 
each of the images: the proportion of the mucosa visual-
ized (visualization sub-score); and the degree of obscura-
tion by bubbles, debris, bile, or other material (obscuration 
sub-score). Each of these parameters was scored on 
a similar three-point scale, with the visualized mucosa 
scored as: >75% = 3, 50-75% = 2, 25-50% = 1, <25% = 
0. Similarly, the degree of obscuration was scored as: <5% 
= 3, 5-25% = 2, 25-50% = 1, >50% = 0. The mean score 
for each of these parameters was obtained by dividing 
the sum of all the images scored by the total number of 
images analyzed, and finally, the average of the 2 param-
eters was calculated as the overall Park cleansing score. In 
addition, the GTT, orocecal transit time (OTT), and SITT 
were measured and compared.
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Outcomes
The primary end-point used in this study was the quality 
of visualization of the mucosal surface, measured as the 
Park score obtained as indicated above.19 In addition, the 
secondary end-points analyzed were the average GTT, 
OTT, and SITT.
Statistical Analysis
Statistical analyses were carried out using the SPSS sta-
tistical analysis package (IBM Corp., Armonk, NY, USA). 
The data are expressed as the mean ± standard devia-
tion (SD) and compared using a one-way analysis of vari-
ance with a Bonferroni’s post hoc multiple comparison 
test. The significance level was set at 5%, and thus, a P 
value < .05 was considered significant.
RESULTS
This study was conducted between January 20017 and 
April 2018. A total of 166 patients fulfilling the inclusion 
criteria were enrolled in the study, 102 females (61.4%) 
and 64 males (38.6%), aged between 16 and 92 years 
(mean, 54.7 ± 19.2). The patients were assigned randomly 
to one of 3 study groups that differed in terms of the pre-
parative protocol used for CE (see “Materials and meth-
ods” section): 55 were allocated to group 1, 55 to group 2, 
and 56 to group 3 (Table 1). Two subjects in group 2 were 
excluded as they refused to ingest the booster, leading 
to a final total of 53 subjects in that group. CE exami-
nations were carried out using either the PillCam(r) SB3 
(n = 113, 68.1%: Given Imaging, Yokneam, Israel) or the 
MiroCam® (n = 53, 31.9%: Intromedic, Seoul, Korea) CE 
system (Table 1).
When visualization in the 3 groups was compared, signifi-
cant differences were evident in the total Park cleansing 
score (F = 2.582, P < .001: Table 2). Indeed, this over-
all difference in the total cleansing score was reflected 
by a significant difference in each of the sub-scores 
that make up this score, the visualization (F = 11.104, 
P < .001) and the obscuration score (F = 5.464, P = .005). 
Pairwise multiple comparisons with a Bonferroni Post 
hoc test revealed that there was a significant difference 
in these 3 variables between group 1 and group 3, with 
significantly lower scores for the 2 individual parameters 
Table 1. Descriptive Analysis of the Patient Cohort
Characteristic Total (N = 166)
Age mean years ± SD (range) 54.7 ± 19.2 (16-92)
Gender, n (%)
 Female 102 (61%)
 Male 64 (39%)
Group according to preparative 
protocol, n (%)
 Group 1 55 (33%)
 Group 2 55 (33%)
 Group 3 56 (34%)
Type of capsule endoscopy system, n 
(%)
 PillCam 113 (68%)
 MiroCam 53 (32%)
Indication
 Ferropenic anemia 55
 Suspected inflammatory bowel 
disease
45
 Obscure bleeding 38
 Reassessment of inflammatory 
bowel disease 
27
 Rendu–Osler–Weber syndrome 1
Group 1, clear liquid diet and fasting-based preparation; group 2, clear liquid 
diet and fasting-based preparation + 1 L of polyethylene glycol/ascorbic acid 
booster; group 3, clear liquid diet and fasting-based preparation + 0.5 L of 
polyethylene glycol/ascorbic acid booster.
Table 2. Effect of the Small-Bowel Preparation Protocols on Transit Time and Mucosa Visualization for CE
Group 1 Group 2 Group 3
F PMean SD Mean SD Mean SD
Visualization sub-score 1.92 0.54 2.18 0.56 2.43 0.61 11 104 <.001
Obscuration sub-score 1.79 0.55 2.04 0.55 2.13 0.56 5464 .005
Total Park score 1.84 0.54 2.07 0.54 2.28 0.59 8290 <.001
GTT 36.58 36.16 41.13 35.57 48.32 43.97 1294 .277
OTT 322.58 100.68 268.16 115.23 289.45 151.36 2671 .072
SITT 280.71 94.70 250.33 113.91 249.95 137.43 1260 .286
SD, standard deviation; GTT, gastric transit time; OTT, orocecal transit time; SITT, small-intestine transit time.
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and for the total Park scores in group 1 than in group 3 
(P < .01: Table 3). By contrast, no significant differences 
in the GTT, OTT, and SITT were detected between the 
3 groups (Table 2).
DISCUSSION
In this study, we set out to determine the efficacy of 
using a basic clear liquid diet and fasting, in conjunction 
with the intake of a PEG/ascorbic acid-based booster, as 
a suitable preparation for CE explorations in a real-world 
situation. The data obtained demonstrate that better 
visualization of the intestinal mucosa can be achieved in 
this manner, with no detriment to the capsule’s intesti-
nal transit. Indeed, ingestion of a reduced volume of the 
booster solution was sufficient to achieve these effects. 
Accordingly, we propose that this approach should be 
explored in greater depth as a more convenient yet effec-
tive preparation for CE explorations in order to maximize 
their success while reducing patient non-compliance and 
abandonment.
Several studies have assessed the effectiveness of dif-
ferent bowel preparations for CE explorations. For some 
years, there has been evidence that bowel preparation 
using PEG solutions improves image quality in CE as 
opposed to protocols that simply involve reduced iron 
intake, a clear liquid diet, and a limited period of fast-
ing.18,20 Indeed, it was proposed that PEG solutions in 
conjunction with oral simethicone or ascorbic acid may 
represent the preparation of choice for CE,6,10 the lat-
ter apparently better tolerated by patients and produc-
ing less adverse effects (e.g., vomiting).8 While different 
meta-analyses concluded that the intake of 2L of PEG 
12 h prior to capsule ingestion improves the visibility of the 
small-bowel mucosa without disturbing the completion 
rate, the influence of such preparation on diagnostic yield 
remains unclear.2,10,14 However, bowel preparation with 2 L 
PEG prior to ingestion of the capsule may be poorly toler-
ated by many patients, possibly leading to a lack of com-
pliance with the preparative protocol. Compliance with 
the preparation for CE procedures is an important issue. 
It is clearly related to successful visualization of the gas-
trointestinal tract and the completion or postponement 
of such explorations.21 These are 2 factors that directly 
affect the diagnostic capacity of these tests and their 
ability to ensure rapid clinical responses, both of which 
are fundamental to the cost-effective treatment of gas-
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The use of the “Park” scoring system19 served to dem-
onstrate the quality of visualization that can be achieved 
in CE explorations following different patient prepara-
tion protocols. Nevertheless, a consensus regarding the 
most appropriate intestinal preparation for CE is still lack-
ing.5,13,21,22 The use of booster solutions in CE explorations 
was originally devised as a method to ensure transit and 
recovery of the capsule during the examination. However, 
here we assessed whether administering a booster solu-
tion of PEG plus ascorbic acid after ingestion of the cap-
sule by patients might complement a clear liquid diet and 
fasting-based bowel preparation and enhance CE visu-
alization. Indeed, in a real-world cohort of patients, the 
quality of small-intestine visualization was significantly 
better in patients who were administered the booster of 
a PEG/ascorbic acid solution once the capsule had been 
seen to have reached the small intestine, in addition to a 
clear liquid diet and fasting-based small-bowel prepara-
tion. In fact, the scores obtained for the 2 parameters that 
make up the overall Park cleansing score and the overall 
cleansing score itself were similar to those obtained using 
a stringent protocol involving the ingestion of 1 liter of 
the PEG/Ascorbic solution in a similar population (article 
under review).
We believe that the approach tested here is likely to be 
more comfortable for the patient and thus, it is likely 
to enhance patient compliance and the success rate of 
these procedures. Although we did not assess the toler-
ability of the protocols used here or the degree of patient 
satisfaction between the 3 groups, the protocol used is 
less aggressive. It involves smaller volumes than other 
preparative regimens involving the use of PEG/Ascorbic 
acid. In fact, the most significant improvements were 
achieved when a smaller volume of the PEG/ascorbic acid 
booster was administered. Importantly, transit times were 
not significantly affected by the different preparative 
protocols, indicating that this protocol is unlikely to com-
promise the battery life of the capsule, nor will it acceler-
ate transit to the extent that it might possibly reduce to 
the accuracy of the exploration. It is possible that the use 
of a PEG/ascorbic acid preparation may favor erosion in 
the small-bowel. However, when we evaluated the small-
bowel erosion in the patients studied here there was no 
clear difference between the individuals that received 
either the clear liquid diet and fasting-based prepara-
tion alone or in conjunction with the PEG/ascorbic acid 
booster. As such, the erosion detected is more likely to 
be due to a prior pathological process rather than to the 
preparation used.
One limitation of this study is that we did not include other 
possible preparative regimens, such as a 2 liter PEG inges-
tion prior to capsule ingestion plus the post-ingestion 
PEG booster. Likewise, we did not compare the booster 
solution used with other similar solutions, such as a PEG/
simethicone solution. Nevertheless, the administration 
of a PEG/Ascorbic acid booster solution after inges-
tion of the capsule in patients who had simply followed 
a clear liquid diet and fasting-based bowel preparation 
for CE improved the quality of mucosal visualization to 
levels achieved previously with more stringent protocols 
(data not shown).10,11 In addition, the protocol followed 
improves visualization and aids the recovery of the cap-
sule, the principal motivation for employing booster solu-
tions, and an effect that is not achieved with the stringent 
protocols used previously.
In summary, a bowel preparation with low iron intake, a 
clear liquid diet the day prior to examination, and 10 h 
fasting, in combination with the administration of 0.5 l of 
a PEG/Ascorbic acid booster solution after capsule inges-
tion, appears to be a suitable preparation to achieve 
adequate cleanliness and good quality visualization of 
the small intestine through CE. Such a preparative regi-
men does not alter the transit time of the capsule, yet 
it potentially provides a user-friendly alternative to the 
more stringent cleansing protocols involving PEG inges-
tion on the day prior to the CE procedure. It is notable 
that the benefits we observed were evident in everyday 
clinical practice; nevertheless, further studies will be 
necessary to confirm these results and to optimize the 
protocol.
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Package leaflet: Information for the User 
 
Moviprep, powder for oral solution 
 
Macrogol 3350, Sodium sulfate anhydrous, Sodium chloride, Potassium chloride, 
Ascorbic acid and Sodium ascorbate 
 
Read all of this leaflet carefully before you start taking this medicine because it contains 
important information for you. 
 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm 
them, even if their signs of illness are the same as yours. 
- If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side 
effects not listed in this leaflet. See section 4. 
 
If you need the information on this leaflet in an alternative format, such as large text, please ring 
Medical Information on 01895 826 606.  
 
What is in this leaflet 
1. What Moviprep is and what it is used for 
2. What you need to know before you take Moviprep 
3. How to take Moviprep 
4. Possible side effects 
5. How to store Moviprep 




1. What Moviprep is and what it is used for 
 
 
Moviprep is a lemon flavoured laxative contained in four sachets. There are two large sachets 
(‘sachet A’) and two small sachets (‘sachet B’). You need all these for one treatment. 
Moviprep is intended for adults to clean the bowel so that they are ready for examination. 





2. What you need to know before you take Moviprep 
 
Do not take take Moviprep 
• if you are allergic (hypersensitive) to the active substances or any of the other 





• if you have an obstruction in your intestine (gut) 
• if you have a perforated gut wall 
• if you have a disorder of stomach emptying 
• if you have paralysis of the gut (often occurs after an operation to the abdomen) 
• if you suffer from phenylketonuria. This is a hereditary inability of the body to use a 
particular amino acid. Moviprep contains a source of phenylalanine 
• if your body is unable to produce enough glucose-6-phosphate dehydrogenase 
• if you have toxic megacolon (a severe complication of acute colitis) 
 
 
Warnings and precautions 
If you are in poor health or have a serious medical condition, you should be particularly 
aware of the possible side effects listed in section 4. Contact your doctor or pharmacist if you 
are concerned. 
 
Talk to your doctor or pharmacist before taking Moviprep if you have any of the following: 
• you need to thicken fluids in order to swallow them safely. 
• a tendency to regurgitate swallowed drink, food or acid from the stomach. 
• kidney disease. 
• heart failure or heart disease including high blood pressure, irregular heartbeats or 
palpitations. 
• thyroid disease 
• dehydration. 
• acute flare of inflammatory bowel disease (Crohn’s disease or ulcerative colitis). 
 
Moviprep should not be given to patients with impaired consciousness without medical 
supervision. 
 
Children and adolescents 
Moviprep should not be taken by children and adolescents aged below 18 years. 
 
Other medicines and Moviprep 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. 
 
If you are taking other medicines take them at least one hour before taking Moviprep or at least 
one hour afterwards because they may be flushed through your digestive system and not work so 
well. 
 
Moviprep with food and drink 
Do not take any solid food from when you start to take Moviprep until after the examination. 
 
When taking Moviprep you should continue to take plenty of fluids. The fluid content of Moviprep 
does not replace your regular liquid intake. 
 
Pregnancy, breast-feeding and fertility 
There are no data on the use of Moviprep during pregnancy or breast-feeding and it should only be 
used if considered essential by your doctor. If you are pregnant or breastfeeding, think you may be 







Driving and using machines 
Moviprep does not affect your ability to drive or use machines. 
 
 
Moviprep contains sodium, potassium and a source of phenylalanine 
This medicine contains 8.4 g sodium (main component of cooking/table salt) per course of 
treatment. (A course of treatment consists of two litres of Moviprep). This is equivalent to 
420% of the recommended maximum daily dietary intake of sodium for an adult. To be 
taken into consideration by patients on a controlled sodium diet. Only a proportion (up to 
2.6 g per course treatment) of sodium is absorbed.  
 
This medicine contains 1.1 g potassium per course of treatment. (A course of treatment consists 
of two litres of Moviprep). To be taken into consideration by patients with reduced kidney 
function or patients on a controlled potassium diet. 
 




3. How to take Moviprep 
 
 
Always take this medicine exactly as your doctor has told you. Check with your doctor or 
pharmacist if you are not sure. The recommended dose is two litres of solution, which is made 
up as follows: 
 
 
This pack contains two clear bags each containing one pair of sachets: sachet A and sachet B. Each 
pair of sachets (A and B) is to be dissolved in water to make a one litre solution. This pack is 
therefore sufficient to make up two litres of Moviprep solution. 
 
Before you take Moviprep, please read carefully the following instructions. You need to know: 
• When to take Moviprep 
• How to prepare Moviprep 
• How to drink Moviprep 
• What you should expect to happen 
 
When to take Moviprep 
Always take this medicine exactly as described in this leaflet or as your doctor has told you. Check 
with your doctor if you are not sure. Your treatment with Moviprep must be completed before 
your examination: 
 
This course of treatment can be taken either as divided or single doses as described below: 
 
For procedures conducted when you are put to sleep (using general anaesthesia): 
 
1. Divided doses: one litre of Moviprep in the evening before and one litre of Moviprep in the 
early morning of the day of the examination. Ensure consumption of Moviprep as well as 
any other clear fluids has finished at least two hours before the start of the examination.  
 
2. Single dose: two litres of Moviprep in the evening before the examination or two litres of 
Moviprep in the morning of the examination. Ensure consumption of Moviprep as well as 






For procedures conducted without the need for putting you to sleep (without using general 
anaesthesia): 
 
1. Divided doses: one litre of Moviprep in the evening before and one litre of Moviprep in the 
early morning of the day of the examination. Ensure consumption of Moviprep as well as any 
other clear fluids has finished at least one hour before the start of the examination. 
 
2. Single dose: two litres of Moviprep in the evening before the examination or two litres of 
Moviprep in the morning of the examination. Ensure consumption of Moviprep has finished 
at least two hours before the start of the examination. Ensure consumption of any clear fluids 
has finished at least one hour before the examination. 
 




How to prepare Moviprep 
•  Open one clear bag and remove the sachets A and B. 
•  Add the contents of BOTH sachet A and sachet B to a measuring jug that holds 1 litre. 
•  Add water to make up to the one litre mark of the container and stir until all the 
powder has dissolved and the Moviprep solution is clear or slightly hazy. This 





How to drink Moviprep 
Drink the first litre of Moviprep solution over one to two hours. Try to drink a glassful every 
10 - 15 minutes. 
 
When you are ready, make up and drink the second litre of Moviprep solution made up with 
the contents of the sachets A and B from the remaining bag. 
 
During the course of this treatment, you are recommended to drink a further one litre of clear 
liquid to prevent you feeling very thirsty and becoming dehydrated. Water, clear soup, fruit 
juice (without pulp), soft drinks, tea or coffee (without milk) are all suitable. These drinks can 
be taken until two hours before the examination under general anaesthesia at the latest and 
until one hour before the examination without general anaesthesia at the latest.  
 
What you should expect to happen 
When you start drinking the Moviprep solution, it is important that you stay close to a toilet. At 
some point, you will start to experience watery bowel movements. This is quite normal and 
indicates that the Moviprep solution is working. The bowel movements will stop soon after you 
have finished drinking. 
 
If you follow these instructions, your bowel will be clear, and this will help you to have a successful 







If you take more Moviprep than you should 
If you take more Moviprep than you should you may develop excessive diarrhoea, which can 
lead to dehydration. Take generous amounts of fluid, especially fruit juices. If you are worried 
contact your doctor or pharmacist. 
 
If you forget to take Moviprep 
If you forget to take Moviprep take the dose as soon as you realise you have not taken it. 
If this is several hours after the time when you should have taken it, contact your doctor or 
pharmacist for advice. When taking Moviprep as divided doses it is important that you 
complete your Moviprep preparation at least; one hour before your examination (without use of 
general anaesthesia), or two hours before your examination (with use of general anaesthesia) . 
When taking all your Moviprep on the morning of the examination as a single dose it is important 
that you complete your Moviprep preparation at least two hours before your examination. 
 
 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
 
4. Possible side effects 
 
Like all medicines Moviprep can cause side effects, although not everybody gets them. It 
is normal to get diarrhoea when you take Moviprep. 
Stop your intake and tell your doctor immediately if you have any of the following side 
effects: 
•  rash or itching 
•  swelling of your face, ankles or other part of your body 
•  palpitations 
•  extreme fatigue 
•  shortness of breath 
 
These are symptoms of a severe allergic reaction. 
 
If you do not have a bowel movement within 6 hours of taking Moviprep, stop the intake and 
contact your doctor immediately. 
 
Other side effects include: 
Very common side effects (may affect more than 1 in 10 people): 
Abdominal pain, abdominal distension, tiredness, feeling generally unwell, soreness of the anus, 
nausea and fever. 
 
Common side effects (may affect up to 1 in 10 people): Hunger, problems sleeping, dizziness, 
headache, vomiting, indigestion, thirst and chills. 
 
Uncommon side effects (may affect up to 1 in 100 people): 
Discomfort, difficulties swallowing, and changes to tests of liver function. 
 
 





because the frequency cannot be estimated from the available data: flatulence (wind), temporary 
increase in blood pressure, irregular heart rhythm or palpitations, dehydration, retching (straining to 
vomit), very low blood sodium levels that can cause convulsions (fits) and changes to the levels of 
salts in the blood such as decreased bicarbonate, increased or decreased calcium; increased or 
decreased chloride and decreased phosphate. Blood potassium and sodium levels could also 
decrease. 
 
These reactions usually only occur for the duration of the treatment. Should they persist, 
consult your doctor. 
 
Allergic reactions may cause a skin rash, itching, reddening of the skin or a nettle rash, swollen 
hands, feet or ankles, headaches, palpitations and shortness of breath. 
 
Reporting of side effects 
 
UK: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible 
side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card 
Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or 
Apple App store.  
 
By reporting side effects you can help provide more information on the safety of this medicine. 
 
 
5. How to store Moviprep 
 
Keep this medicine out of the sight and reach of children. 
 
 
Do not use this medicine after the expiry date which is stated on the carton after “EXP”.  Please 
note that the expiry dates may be different for the different sachets. The expiry date refers to the 
last day of the month. 
 
Keep Moviprep sachets at room temperature (below 25ºC). 
 
After you have dissolved Moviprep in the water, the solution may be stored (keeping covered) at 
room temperature (below 25°C). It may also be stored in the fridge (2°C -8°C). Do not keep it 
for more than 24 hours. 
 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. 
 
 
6. Contents of the pack and other information 
 
What Moviprep contains 
Sachet A contains these active substances: 
 
Macrogol (also known as polyethylene glycol) 3350  100 g 
Sodium sulfate anhydrous 7.500 g 
Sodium chloride 2.691 g 








Sachet B contains these active substances: 
 
Ascorbic acid 4.700 g 
Sodium ascorbate 5.900 g 
 
The concentration of electrolyte ions when both sachets are made up to one litre of solution is as 
follows: 
 
Sodium 181.6 mmol/L (of which not more than 56.2 mmol is absorbable) 
Chloride 59.8 mmol/L 
Sulfate                 52.8 mmol/L 
Potassium           14.2 mmol/L 
Ascorbate            29.8 mmol/L 
 
The other ingredients are 
Lemon flavouring (containing maltodextrin, citral, lemon oil, lime oil, xanthan gum, vitamin E), 
aspartame (E951) and acesulfame potassium (E950) as sweeteners. For further information refer 
to section 2. 
 
 
What Moviprep looks like and contents of the pack 
This pack contains two clear bags each containing one pair of sachets: sachet A and sachet B. 
Each pair of sachets (A and B) is to be dissolved in one litre of water. 
Moviprep powder for oral solution in sachets is available in pack sizes of 1, 10, 40, 80, 160 and 320 
packs of a single treatment. Hospital packs of 40 single treatments. Not all pack sizes may be 
marketed. 
 
Marketing Authorisation Holder and Manufacturer 
 
 
Marketing Authorisation Holder: 
 
Norgine Pharmaceuticals Limited 
Norgine House,  
Widewater Place, 

















Norgine B.V., Antonio Vivaldistraat 150, 1083 HP Amsterdam, The Netherlands. 
 
 
The medicinal product is authorised in the Member States of the EEA under the 
following names: 
 
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, 
Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, 





This leaflet was last revised in November 2019 
 
----------------------------------------------------------------------------------------------------------------------------- 
The following information is intended for healthcare professionals only: 
Moviprep should be administered with caution to fragile patients in poor health or patients with 
serious clinical impairment such as: 
• impaired gag reflex, or with a tendency to aspiration or regurgitation 
• impaired consciousness 
• severe renal insufficiency (creatinine clearance <30 mL/min) 
• cardiac impairment (NYHA grade III or IV) 
• those at risk of arrhythmia,  for example those on treatment for cardiovascular disease or 
who have thyroid disease 
• dehydration 
• severe acute inflammatory bowel disease 
 
The presence of dehydration or electrolyte shifts should be corrected before the use of 
Moviprep. 
 
Semi-conscious patients or patients prone to aspiration or regurgitation should be closely 
observed during administration especially if this is via a nasogastric route. 
 
Moviprep should not be given to unconscious patients. 
